drugset / Trial / NCT05637086
Clinical Study Evaluating Safety of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy
Phase 2
Recruiting
90 enrolled
Mostafa Bahaa
Principal Investigator Maha Ahmed Younis, PhD Pharmacy Practice Department- Horus University · collabTanta University · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Epilepsy is a chronic neurological disorder affecting millions of people all over the world. Epileptic seizures are caused by abnormal synchronized electrical neuronal discharges that could be either focal or widespread. Pathogenesis of epilepsy involves multiple processes including genetics, oxidative stress, ion channels, neuroinflammation, and cellular damage through autophagy and apoptosis. Neuroinflammation is considered one of the most important factors contributing critically to epileptogenesis.
Timeline
- Start
- 2022-12-20
- Primary completion
- 2026-12-20
- Completion
- 2027-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Celecoxib | Other / unclassified | 200 mg | — |
| Comparator | Pentoxifylline | Small molecule | 400 mg | — |
| Background | Phenytoin | Unknown | 100 mg | — |